EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer

2012 ◽  
Vol 12 (11) ◽  
pp. 1429-1435 ◽  
Author(s):  
Marco Bartolotti ◽  
Enrico Franceschi ◽  
Alba Ariela Brandes
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Tyrosine Kinase ◽  
Small Cell Lung Cancer ◽  
Receptor Tyrosine Kinase ◽  
Kinase Inhibitors ◽  
Egf Receptor ◽  
Small Cell ◽  
Small Cell Lung ◽  
Receptor Tyrosine Kinase Inhibitors

Radiotherapy of non-small-cell lung cancer in the era ofEGFRgene mutations and EGF receptor tyrosine kinase inhibitors

2015 ◽  
Vol 11 (16) ◽  
pp. 2329-2342 ◽  
Author(s):  
Ilaria Moschini ◽  
Cristina Dell'Anna ◽  
Pier Luigi Losardo ◽  
Paola Bordi ◽  
Nunziata D'Abbiero ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tyrosine Kinase ◽  
Small Cell Lung Cancer ◽  
Tyrosine Kinase Inhibitors ◽  
Receptor Tyrosine Kinase ◽  
Kinase Inhibitors ◽  
Egf Receptor ◽  
Small Cell ◽  
Small Cell Lung ◽  
Receptor Tyrosine Kinase Inhibitors

scholarly journals RADI-19. The Incidence of New Brain Metastases in Patients with Non-Small Cell Lung Cancer Following Discontinuation of Systemic Therapy

2021 ◽  
Vol 3 (Supplement_3) ◽  
pp. iii22-iii22
Author(s):  
Dennis London ◽  
Dev Patel ◽  
Bernadine Donahue ◽  
Ralph Navarro ◽  
Jason Gurewitz ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Tyrosine Kinase ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Receptor Tyrosine Kinase ◽  
Systemic Therapy ◽  
Cox Regression ◽  
Small Cell ◽  
Small Cell Lung

Abstract Purpose Patients with non-small cell lung cancer (NSCLC) metastatic to the brain increasingly are living longer due to improvements in systemic therapy and local modalities. The risk of new brain metastases when these patients stop systemic therapy is unknown. Recognizing patterns of new tumor occurrence is necessary to determine the frequency of follow-up and the need for further treatment. Methods We included patients in a prospective registry who had non-small cell lung cancer (NSCLC) brain metastases, discontinued systemic therapy for at least 90 days, and underwent active surveillance. 63 patients with 73 off-periods were studied. The risk factors for the development of new tumors were determined using Cox regression and multi-state Markov modeling. Results The median time to new brain metastases off systemic therapy was 16.0 months. The probability of developing an additional new tumor at 6, 12, and 18 months was 26%, 40%, and 53%, respectively. There were no additional new tumors 22 months after stopping therapy. Patients who discontinued therapy due to intolerance or progression of the disease and those with mutations in RAS or receptor tyrosine kinase pathways (e.g. KRAS, EGFR) were more likely to develop new tumors (HR: 2.21, 95% CI: 1.25–3.91, p=6.3 x 10–3; HR: 2.03, 95% CI: 1.09–3.77, p=0.026, respectively). Conclusion The rate of new brain metastases from NSCLC in patients off systemic therapy decreases over time and is uncommon 2 years after cessation of cancer therapy. Patients who stop therapy due to toxicity or who have RAS or receptor tyrosine kinase pathway mutations have a higher rate of new metastases and should be followed more closely.

Sign in / Sign up

Export Citation Format

Share Document